M. de Béthune

发表

Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

H. M. Vinkers, A. D. Clark, R. Pauwels, 2004, Journal of medicinal chemistry.

Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues.

R. Pauwels, E. Arnold, F. Daeyaert, 2001, Bioorganic & medicinal chemistry letters.

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans, 2004, Antimicrobial Agents and Chemotherapy.

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

Stephen H Hughes, Peter Williams, Paul J Lewi, 2005, Journal of medicinal chemistry.

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

P. Harrigan, K. Hertogs, R. Pauwels, 1998, The Journal of infectious diseases.

Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).

R. Pauwels, E. Arnold, P. Janssen, 2001, Bioorganic & medicinal chemistry letters.

TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments

R. Pauwels, K. Andries, M. de Béthune, 2005, Journal of Virology.

Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120.

H. Schuitemaker, E. De Clercq, R. Pauwels, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor

R. Shattock, P. Fletcher, M. de Béthune, 2008, Antimicrobial Agents and Chemotherapy.

Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity.

E. De Clercq, R. Pauwels, D. Meijer, 1996, Biochimica et biophysica acta.

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

S. Kostense, P. Quax, M. Havenga, 2003, Journal of Virology.

Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.

E. De Clercq, R. Pauwels, D. Meijer, 1995, The Journal of infectious diseases.

RT-PCR for Amplification of Specific Fragments of HIV-1 Genome.

K. Hertogs, M. de Béthune, 2000, Methods in molecular medicine.

Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.

Christopher M. Bailey, K. Anderson, M. de Béthune, 2006, Biochemistry.

Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation

F. Belardelli, M. de Béthune, S. Vella, 2003, AIDS.

Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.

K. Hertogs, C. Nguyen, K. Andries, 2009, Journal of medicinal chemistry.

Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects

Frank Goebel, F. Goebel, M. de Béthune, 2006, AIDS.

Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.

R. Pauwels, E. Arnold, F. Daeyaert, 2005, Journal of medicinal chemistry.

Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

Celia A Schiffer, Hilde Azijn, Rudi Pauwels, 2005, Journal of medicinal chemistry.

Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

R. Pauwels, E. Arnold, F. Daeyaert, 2001, Bioorganic & medicinal chemistry letters.

Antiviral activity of Hawaiian medicinal plants against human immunodeficiency Virus Type-1 (HIV-1).

E. De Clercq, R. Pauwels, M. Witvrouw, 1996, Phytomedicine : international journal of phytotherapy and phytopharmacology.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

M. de Béthune, 2010, Antiviral research.

4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.

R. Pauwels, C. Nguyen, C. Monneret, 2004, Journal of Medicinal Chemistry.

A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

Brendan Larder, Stuart Bloor, Frank Peeters, 1998, Antimicrobial Agents and Chemotherapy.

Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent

R. Ptak, E. De Clercq, B. Rosenwirth, 2008, Antimicrobial Agents and Chemotherapy.

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Dirk Jochmans, Hilde Azijn, Gaston Picchio, 2009, Antimicrobial Agents and Chemotherapy.

TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates

Dirk Jochmans, Hilde Azijn, Rudi Pauwels, 2005, Antimicrobial Agents and Chemotherapy.

Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor

Celia A. Schiffer, C. Schiffer, E. Nalivaika, 2004, Journal of Virology.

Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride

K. Hertogs, R. Pauwels, S. Staszewski, 1998, Antimicrobial Agents and Chemotherapy.

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.

M. de Béthune, A. Hill, G. Picchio, 2008, Journal of acquired immune deficiency syndromes.

A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides.

P. Lewi, G. Vanham, L. Heyndrickx, 2007, Antiviral research.

Characterisation of the binding of virginiamycin S to Escherichia coli ribosomes.

K. Nierhaus, M. de Béthune, 1978, European journal of biochemistry.

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol

Johnson Mak, Gilda Tachedjian, J. Mak, 2006, PLoS pathogens.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

M. de Béthune, H. Azijn, J. Vingerhoets, 2009, Antiviral therapy.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

M. de Béthune, G. Picchio, I. Dierynck, 2009, AIDS.

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

Hilde Azijn, M. de Béthune, M. Peeters, 2010, AIDS.

The M184 V mutation in HIV‐1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross‐resistance to nucleoside analogue RT inhibitors

P. Harrigan, K. Hertogs, R. Pauwels, 1998, AIDS.

Charge modification of plasma and milk proteins results in antiviral active compounds

E. De Clercq, R. Pauwels, M. Harmsen, 1999, Journal of peptide science : an official publication of the European Peptide Society.

Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

M. de Béthune, H. Azijn, J. Vingerhoets, 2010, AIDS research and human retroviruses.

Virological Characterization of Patients Failing Darunavir/Ritonavir or Lopinavir/Ritonavir Treatment in the Artemis Study: 96-Week Analysis

M. de Béthune, T. van de Casteele, L. Lavreys, 2011, Antiviral therapy.

Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

M. Opravil, M. de Béthune, A. Pozniak, 2008, AIDS research and human retroviruses.

Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.

K. Hertogs, R. Pauwels, E. Arnold, 2005, Journal of medicinal chemistry.

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

Celia A Schiffer, Hilde Azijn, Rudi Pauwels, 2005, Journal of medicinal chemistry.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

C. Cohen, M. de Béthune, D. Berger, 2009, AIDS.

Resistance profile of darunavir: combined 24-week results from the POWER trials.

Tony Vangeneugden, Gaston Picchio, M. de Béthune, 2008, AIDS research and human retroviruses.

Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir

G. D. Miralles, M. de Béthune, S. De Meyer, 2008, Journal of acquired immune deficiency syndromes.

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

M. de Béthune, G. Picchio, I. Dierynck, 2010, Antiviral therapy.

Discovery, development and characterization of agents active against the AIDS virus.

E. De Clercq, R. Pauwels, K. Andries, 1995, Journal of receptor and signal transduction research.

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.

M. de Béthune, H. Azijn, J. Vingerhoets, 2010, AIDS research and human retroviruses.

Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy

A. Rieger, M. de Béthune, A. Pozniak, 2008, Antiviral therapy.

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

S. Kostense, P. Quax, M. Havenga, 2003, Journal of Virology.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

Marie-Pierre de Béthune, M. de Béthune, M. D. Béthune, 2010, Antiviral research.